Tuesday, 23 Jan 2018

You are here

Lymphopenia and Steroids Increase the Risk of Pneumocystis Jiroveci in Systemic Rheumatic Diseases

It is well-known that patients with systemic autoimmune diseases are at risk for Pneumocystis jirovecii pneumonia (PJP) and although infrequent, it carries a high mortality. A new study shows lymphopenia and steroid use increases the risk of PJP.

Prior to 1990 reports were rare, however increasing use of immunosuppression, particularly in combinations, improved diagnostic techniques and awareness of the disease have led to improved documentation.

Unlike in HIV where CD4 counts guide when to initiate PJP prophylaxis, there exists no biomarker in the rheumatology world though there has been a focus on the negative association between lymphocyte counts with PCP occurrence in immunocompromised hosts.  

In a recent edition of Seminars in Arthritis and Rheumatism, Tadros et al. presented the results of a case-control study that examined the differences in characteristics and peripheral blood parameters between patients with systemic rheumatic disease who did or did not develop PJP. The authors collected data between 2002 and 2013 from a single center in Melbourne, Australia to match 11 patients identified as having a systemic rheumatologic disease and PJP in a 1:4 ratio with matched controls.

After adjustments for glucocorticoid exposure and CRP, they found that lymphocyte count on admission (0.4 vs. 1.3; p=0.04) and nadir (0.2 vs. 0.8x109/L; p=0.05) were significantly lower in patients with PJP compared to controls.

We know that glucocorticoids are also a risk factor for PJP (and can cause lymphopenia, at least transiently), but this study is the first to show that lymphopenia is a risk factor independent of GC use.

While no consensus guidelines exist, monitoring lymphocyte counts may assist us in deciding when to initiate PJP prophylaxis; although it is unclear what cutoff values should be used.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Stroke Risk Confirmed in SLE

The most common cerebrovascular events (CVEs) seen among a large cohort of patients with systemic lupus erythematosus (SLE) were stroke and transient ischemia, and the majority of these events were attributable to the disease itself, a multinational study determined.

Stem Cell Transplant Succeeds in Scleroderma

Myeloablative autologous stem cell transplantation was significantly more effective than 12 months of cyclophosphamide among patients with severe scleroderma, an open-label multicenter study found.

Stroke Risk Highest in the First Year of Lupus (Best of 2017)

Arkema et al has published in Annals of Rheumatic Disease a study showing that ischaemic and haemorrhagic stroke (CVA) is elevated in systemic lupus erythematosus (SLE) compared with the general population, especially in the first year. 

Death Rates from Lupus Remain Disproportionately High (Best of 2017)

The Annals of Internal Medicine reports that despite improving trends in mortality, death rates from systematic lupus erythematosus (lupus) remain high compared to those in the general population, and disparities persist between subpopulations and geographic regions. Underreporting of lupus on death certificates may have resulted in underestimates of mortality rates. 

Registry Efficacy of Rituximab in Refractory SLE

Despite large randomized trials failing to show the efficacy of RTX in SLE (LUNAR, EXPLORER), uncontrolled observational data suggests possible efficacy and safety of RTX in refractory SLE.